SCHEMBL4818003

SCHEMBL4818003

[NH][CH]c1ccc(Cl)c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.58
NPFFR2 Q9Y5X5 2/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CHAT P28329 1/20 0.44
AHR P35869 2/20 0.43
TP53 P04637 1/20 0.43
PYGL P06737 3/20 0.40
TSHR P16473 2/20 0.40
CYP3A4 P08684 1/20 0.40
HSD17B10 Q99714 1/20 0.40
IGF1R P08069 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KDM4A O75164 1/20 0.39
KDM4B O94953 1/20 0.39
THRB P10828 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
G6PC1 P35575 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4817991 0.79 ALDH1A1 (0.58) ALDH1A1NPFFR2KMT2ANPSR1CHAT
SCHEMBL4818010 0.79 ALDH1A1 (0.58) ALDH1A1NPFFR2KMT2ANPSR1CHAT
SCHEMBL10973255 0.78 ALDH1A1 (0.64) ALDH1A1NPFFR2KMT2ANPSR1CHAT
SCHEMBL10973260 0.78 ALDH1A1 (0.64) ALDH1A1NPFFR2KMT2ANPSR1CHAT
SCHEMBL3298582 0.78 ALDH1A1 (0.64) ALDH1A1NPFFR2KMT2ANPSR1CHAT
SCHEMBL9720849 0.76 CHAT (0.67) ALDH1A1NPFFR2KMT2ANPSR1CHAT
SCHEMBL8580658 0.76 ALDH1A1 (0.61) ALDH1A1NPFFR2KMT2ANPSR1CHAT
SCHEMBL9720852 0.76 CHAT (0.67) ALDH1A1NPFFR2KMT2ANPSR1CHAT
SCHEMBL48577 0.74 ALDH1A1 (1.00) ALDH1A1NPFFR2KMT2ANPSR1CHAT
SCHEMBL11123079 0.74 ALDH1A1 (0.58) ALDH1A1NPFFR2KMT2ANPSR1CHAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090847-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS PLIVA D.D. (HR) 2008-04-17 US claimed
EP-1432713-A4 FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS ESSENTIAL THERAPEUTICS INC (US) 2005-05-11 EP claimed
EP-1411949-A4 8/17 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS ESSENTIAL THERAPEUTICS INC (US) 2004-11-24 EP claimed
EP-1432713-A2 FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS Essential Therapeutics, Inc. (US) 2004-06-30 EP claimed
EP-1411949-A2 8/17 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS Essential Therapeutics, Inc. (US) 2004-04-28 EP claimed
US-20030181470-A1 Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors ESSENTIAL THERAPEUTICS, INC. 2003-09-25 US claimed
US-20030176436-A1 Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof ALA PAUL J (DE) 2003-09-18 US claimed
WO-2003002064-A2 FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS ESSENTIAL THERAPEUTICS, INC. (US) 2003-01-09 WO claimed
WO-2003001887-A2 FUSED PYRIMIDINES AS D-ALANYL-D-ALANINE LIGASE INHIBITORS ESSENTIAL THERAPEUTICS, INC. (US) 2003-01-09 WO claimed
US-20080090847-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS PLIVA D.D. (HR) 2008-04-17 US disclosed
US-7345048-B2 Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors PLIVA D.D. (HR) 2008-03-18 US disclosed
EP-1432713-A4 FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS ESSENTIAL THERAPEUTICS INC (US) 2005-05-11 EP disclosed
EP-1411949-A4 8/17 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS ESSENTIAL THERAPEUTICS INC (US) 2004-11-24 EP disclosed
EP-1432713-A2 FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS Essential Therapeutics, Inc. (US) 2004-06-30 EP disclosed
EP-1411949-A2 8/17 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS Essential Therapeutics, Inc. (US) 2004-04-28 EP disclosed
US-20030181470-A1 Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors ESSENTIAL THERAPEUTICS, INC. 2003-09-25 US disclosed
US-20030176436-A1 Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof ALA PAUL J (DE) 2003-09-18 US disclosed
WO-2003001887-A2 FUSED PYRIMIDINES AS D-ALANYL-D-ALANINE LIGASE INHIBITORS ESSENTIAL THERAPEUTICS, INC. (US) 2003-01-09 WO disclosed
WO-2003002064-A2 FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS ESSENTIAL THERAPEUTICS, INC. (US) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181470-A1 Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors AAAS, ALAD, NAALAD2 ALDH1A1 1974/4885NPFFR2 4627/4885KMT2A 2293/4885
US-20030176436-A1 Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof DHFR, DHODH, DPYD ALDH1A1 122/4885NPFFR2 3593/4885KMT2A 1134/4885
US-20080090847-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AS D-ALANYL-D-ALANINE LIGASE INHIBITORS AAAS, ALAD, NAALAD2 ALDH1A1 1974/4885NPFFR2 4627/4885KMT2A 2293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.